JMP Securities analyst Constantine Davides lowered the firm’s price target on AMN Healthcare (AMN) to $34 from $47 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm reduced its 2025 EBITDA estimate to $235M from $250M on slightly more conservative operating margin assumptions and sees 2026 revenue of $2.66B on EBITDA of $255M, and its more conservative multiple is the result of continued near-term secular pressures within healthcare staffing, the analyst says.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN: